$0.83
1.30% today
Nasdaq, Apr 03, 06:19 pm CET
ISIN
US50107A1043
Symbol
KRON
Sector
Industry

Kronos Bio Inc Stock price

$0.84
-0.09 9.62% 1M
-0.16 16.31% 6M
-0.11 12.00% YTD
-0.43 34.17% 1Y
-6.68 88.88% 3Y
-18.16 95.60% 5Y
-18.16 95.60% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.03 3.47%
ISIN
US50107A1043
Symbol
KRON
Sector
Industry

Key metrics

Market capitalization $50.97m
Enterprise Value $-36.55m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.56
EV/Sales (TTM) EV/Sales -3.71
P/S ratio (TTM) P/S ratio 5.17
P/B ratio (TTM) P/B ratio 0.58
Revenue growth (TTM) Revenue growth 56.62%
Revenue (TTM) Revenue $9.85m
EBIT (operating result TTM) EBIT $-63.43m
Free Cash Flow (TTM) Free Cash Flow $-65.44m
Cash position $112.42m
EPS (TTM) EPS $-1.43
P/E forward negative
Short interest 1.61%
Show more

Is Kronos Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Kronos Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Kronos Bio Inc forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a Kronos Bio Inc forecast:

Hold
100%

Financial data from Kronos Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
9.85 9.85
57% 57%
100%
- Direct Costs 1.72 1.72
48% 48%
17%
8.13 8.13
174% 174%
83%
- Selling and Administrative Expenses 22 22
38% 38%
228%
- Research and Development Expense 47 47
42% 42%
481%
-62 -62
47% 47%
-627%
- Depreciation and Amortization 1.72 1.72
48% 48%
17%
EBIT (Operating Income) EBIT -63 -63
47% 47%
-644%
Net Profit -86 -86
24% 24%
-874%

In millions USD.

Don't miss a Thing! We will send you all news about Kronos Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kronos Bio Inc Stock News

Neutral
GlobeNewsWire
16 days ago
SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results.
Neutral
GlobeNewsWire
4 months ago
– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D.
Neutral
GlobeNewsWire
5 months ago
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures –
More Kronos Bio Inc News

Company Profile

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, which engages in the provision of discovery and development of novel cancer therapeutics products. Its pipeline includes hematologic transcription factors, small cell, prostate cancer, and MYC-driven cancers. The company was founded by Angela Koehler and Joshua Kazam in 2017 and is headquartered in Cambridge, MA.

Head office United States
CEO Deborah Knobelman
Employees 10
Founded 2017
Website www.kronosbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today